Pegylated arginine deiminase treatment of patients with metastatic melanoma: Results from phase I and II studies
Pegylated arginine deiminase treatment of patients with metastatic melanoma: Results from phase I and II studies
复制标题
DOI：
10.1200/jco.2005.02.0933
复制
发表时间：
2005-10-20
影响因子：
45.3
通讯作者：
Logan, TF
中科院分区：
文献类型：
--
作者：
Ascierto, PA;Scala, S;Logan, TF
目的
转移性黑色素瘤患者预后不良。许多人类黑色素瘤对精氨酸存在营养缺陷，而精氨酸在人类中并非必需氨基酸。我们假设这种营养缺陷可用于治疗。一种与聚乙二醇结合的新型氨基酸降解酶（精氨酸脱亚胺酶，ADI - SS PEG 20,000 mw）被用于降低转移性黑色素瘤患者的血浆精氨酸水平。
患者与方法
进行了两项队列剂量递增研究。美国的一项I期研究纳入了15名患者，意大利的一项I - II期研究纳入了24名患者。意大利患者还接受了随后的两个治疗周期，每个周期包括每周一次、每次160 U/m²的四次注射。这些研究的目的是确定ADI - SS PEG 20,000 mw的药代动力学（PK）、药效学（PD）、安全性以及抗肿瘤活性。
结果
药代动力学和药效学研究表明，160 U/m²的剂量可使血浆精氨酸从约130 μmol/L的基础水平降低至低于2 μmol/L，并至少持续7天；一氧化氮水平也有所降低。没有直接归因于该药物的3级或4级毒性。24名I - II期患者中有6名对治疗有反应（5名部分缓解和1名完全缓解；缓解率为25%），并且生存期延长。
结论
在转移性黑色素瘤患者中消除所有可检测到的血浆精氨酸具有良好的耐受性，并且可能对这种癌症的治疗有效。有必要在更多的转移性黑色素瘤患者中对ADI - SS PEG 20,000 mw进行进一步测试。
Purpose Individuals with metastatic melanoma have a poor prognosis. Many human melanomas are auxotrophic for arginine, and arginine is not an essential amino acid in humans. We hypothesized that this auxotrophy may be therapeutically exploited. A novel amino acid-degrading enzyme (arginine deiminase) conjugated to polyethylene glycol (ADI-SS PEG 20,000 mw) was used to lower plasma arginine in individuals with metastatic melanoma.Patients and Methods Two cohort dose-escalation studies were performed. A phase I study in the United States enrolled 15 patients, and a phase I to II study in Italy enrolled 24 patients. The Italian patients also received two subsequent cycles of treatment, each consisting of four once-weekly injections of 160 U/m(2). The goals of these studies were to determine pharmacokinetics (PK) pharmacodynamics (PD), safety, and the antitumor activity of ADI-SS PEG 20,000 mw.Results PK and PD studies indicated that a dose of 160 U/m(2) lowered plasma arginine from a resting level of approximately 130 mu mol/L to less than 2 mu mol/L for at least 7 days; nitric oxide levels also were lowered. There were no grade 3 or 4 toxicities directly attributable to the drug. Six of 24 phase I to II patients responded to treatment (five partial responses and one complete response; 25% response rate) and also had prolonged survival.Conclusion Elimination of all detectable plasma arginine in patients with metastatic melanoma was well tolerated and may be effective in the treatment of this cancer. Further testing of ADI-SS PEG 20,000 mw in a larger population of individuals with metastatic melanoma is warranted.